Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Forest Tudorza Pressair Approval For COPD Includes Post-marketing CV Safety Study

This article was originally published in The Pink Sheet Daily

Executive Summary

The twice-daily aclidinium, a long-acting antimuscarinic agent, should be available to wholesalers in the fourth quarter.

You may also be interested in...



Forest COPD Combo Hits Roadblock En Route To NDA Filing

Forest is delaying submission of an NDA for aclidinium/formoterol to resolve FDA concerns about the formulation’s chemistry, manufacturing and control specifications.

GSK’s Anoro Ellipta Needs CV Postmarket Study, FDA Panel Says In Endorsement

Pulmonary-Allergy Drugs Advisory Committee votes in favor of what could become the first-approved LAMA/LABA combo for COPD but wants postmarket safety study in patients with more severe cardiovascular disease.

Forest COPD Combo Hits Roadblock En Route To NDA Filing

Forest is delaying submission of an NDA for aclidinium/formoterol to resolve FDA concerns about the formulation’s chemistry, manufacturing and control specifications.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074423

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel